Welcome to our dedicated page for Lumexa Imaging Holdings SEC filings (Ticker: LMRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lumexa Imaging is a nationwide provider of diagnostic imaging services and outpatient medical imaging, and its filings offer detailed insight into its capital structure, governance and material agreements.
Investors can review Lumexa’s registration statement and related documents associated with its initial public offering on the Nasdaq Global Select Market, as well as subsequent Current Reports on Form 8-K. For example, recent 8-K filings describe the completion of the IPO, the execution of an underwriting agreement and stockholders agreement, adoption of an Amended and Restated Certificate of Incorporation and Bylaws, and entry into indemnification agreements with directors and executive officers.
Another 8-K filing outlines an amended credit agreement that provides Lumexa Imaging subsidiaries with a secured term loan facility and a secured revolving credit facility. The filing details interest rate terms, maturities, restrictive covenants and a leverage-related financial covenant, along with guarantees and security interests from substantially all wholly owned subsidiaries, subject to specified exceptions. These disclosures help readers understand Lumexa’s borrowing arrangements and related obligations.
On this page, users can track Lumexa Imaging’s Forms 10-K and 10-Q when filed, along with additional 8-Ks, proxy statements and other submissions. Stock Titan enhances these documents with AI-powered summaries that explain key sections, highlight important covenants and capital structure details, and make lengthy filings more accessible. The platform also surfaces insider transaction reports on Form 4, enabling users to monitor equity transactions by Lumexa’s directors and executive officers in one place.
Lumexa Imaging Holdings, Inc. reported that one of its directors holds two stock option grants over the company’s common stock. The event date for this insider ownership report is 12/11/2025.
Each stock option (right to buy) relates to 22,222 shares of common stock at an exercise price of $18.5 per share and has an expiration date of 12/10/2035. One grant vests in five substantially equal annual installments from April 26, 2022, and the other vests in five substantially equal annual installments from April 1, 2024, in each case subject to the director’s continued service with the company.
Lumexa Imaging Holdings, Inc. director reports beneficial ownership of a stock option covering 22,222 shares of common stock at an exercise price of $18.5 per share, expiring on 12/10/2035.
The option vests in five substantially equal annual installments starting from a vesting commencement date of March 1, 2025, and each installment requires the director to continue serving with the company. The option is held directly.
Lumexa Imaging Holdings, Inc. filed an initial statement of beneficial ownership for Welsh, Carson, Anderson & Stowe–affiliated entities that are identified as both directors and 10% owners. These reporting persons disclose indirect holdings of Lumexa Imaging common stock through Common Units of Lumexa Imaging Equity Holdco, LLC (Holdings LLC), where each nine Common Units represent the right to acquire one share of common stock held by Holdings LLC.
The filing lists multiple blocks of common stock underlying these derivative securities, including 17,646,994 shares attributable to Welsh, Carson, Anderson & Stowe XII, L.P., 3,219,023 shares for Welsh, Carson, Anderson & Stowe XII Cayman, L.P., and 3,267,506 shares for WCAS Co-Invest Holdco, L.P. After Lumexa Imaging’s initial public offering and a 180-day lock-up period, Holdings LLC may distribute its common stock pro rata to remaining equity holders, at which time these indirect interests may be settled into Lumexa Imaging shares in connection with such a distribution.